Antifibrotic effects of Ivabradine for myocardium in ischemic chronic heart failure
Heart failure (HF) is the end stage of most diseases of the cardiovascular system and is a major cause of morbidity and mortality. Ivabradine (Iva) – the new medication with sinus If-channels inhibition effects. Nowadays Iva is present in ESC recommendation for HF and chronic coronary disease management. The purpose of study was to evaluate of potential antifibrotic effects of Ivabradine for myocardium in case of chronic heart failure. On twelve-week-old male Rattus Norvegicus L. rats, weighing 220–240 g, HF were modeling. This study shows that Ivabradine treatment of rats with HF prevented anatomical remodeling. Such beneficial effects of Ivabradine on cardiac remodeling open new clinical perspectives for the treatment of severe HF.
How to cite this article:
Sergiy Fedorov. Antifibrotic effects of Ivabradine for myocardium in ischemic chronic heart failure. Pharma Innovation 2016;5(2):39-41.